Restricted accessReview articleFirst published online 2012-04
Natural Polypill Xuezhikang : Its Clinical Benefit and Potential Multicomponent Synergistic Mechanisms of Action in Cardiovascular Disease and Other Chronic Conditions
Polypill has been a hot issue since it was first advanced in 2003. This new concept immediately spurred a worldwide discussion. Xuezhikang is a partially purified extract of fermented red yeast rice (Monascus purpureus). It is composed of 13 kinds of natural statins, unsaturated fatty acids, ergosterol, amino acids, flavonoids, alkaloid, trace element, and other substances, and thus could be regarded as a natural lipid-lowering polypill. Interestingly, Xuezhikang in the China Coronary Secondary Prevention Study trial lowered lipid levels less as compared with provastatin in the Cholesterol and Recurrent Events trial, but seemed to gain more benefit in reducing the cardiovascular events and the risk of death from cancer. In recent years, Xuezhikang has been further demonstrated to have additional health benefits and thus raised great interest. This article reviews the clinical benefits of Xuezhikang and the potential multicomponent synergetic mechanism. The authors hold that polypill is anticipated to be a more effective and feasible way to treat complicated diseases.
Get full access to this article
View all access options for this article.
References
1.
World Health Organization. The World Health Report 2003—Shaping the Future. www.who.int/whr/2003/en/. 2012 April 2.
DeziiCM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care, 2000; 9,suppl:S2–S6.
4.
WaldNJ, LawMR. A strategy to reduce cardiovascular disease by more than 80%BMJ, 2003; 326:1419.
5.
RodgersA. A cure for cardiovascular disease?BMJ, 2003; 326:1407–1408.
6.
WillisJ. Polypill debate continues: Concept is a fascinating thought experiment. BMJ, 2004; 328:289.
7.
ReddyKS. The preventive polypill: Much promise, insufficient evidence. NEJM, 2007; 356:212.
8.
GazianoTA, OpieLH, WeinsteinMC. Cardiovascular disease prevention with a multidrug regimen in the developing world: A cost-effectiveness analysis. Lancet, 2006; 368:679–686.
9.
SolimanEZ, MendisS, DissanayakeWP, SomasundaramNP, GunaratnePS, JayasingneIKet al.A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization. Trials, 2011; 12:3.
10.
ZhangML, DuanZW, XieSM. Study on the active ingredient of Xuezhikang. Chin J New Drugs (Chin), 1998; 7:213–214.
11.
JournoudM, JonesPJ. Red yeast rice: A new hypolipidemic drug. Life Sci, 2004; 74:2675.
12.
LiuJ, ZhangJ, ShiYet al.Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: A meta-analysis of randomized controlled trials. Chin Med, 2006; 1:4.
13.
LuZ, KouW, DuBet al.Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol, 2008; 101:1689–1693.
14.
Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chin J Cardiol (Chin), 2007; 35:390–419.
15.
PfefferMA, SacksFM, MoyéLAet al.Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol, 1995; 76:98C–106C.
16.
LuZL, XuZM, KouWR, ZhaoSP. Advance in basic and clinical research of Xuezhikang Capsule. Chin J Integr Med, 2006; 12:85–93.
17.
PhillipsonBE, RothrockDW, ConnorWEet al.Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. NEJM, 1985; 312:1210–1216.
18.
DaiY, YanHH, WangF. Effects of α-linolenic acid and γ-linolenic acid on the blood-lipid levels in hyperlipidemia people. Prog Mod Biomed (Chin), 2009; 9:4492–4495.
19.
GriffinMD, SandersTA, DaviesIGet al.Effects of altering the ratio of dietary n-6 to n-3 fatty acids on insulin sensitivity, lipoprotein size, and postprandial lipemia in men and postmenopausal women aged 45–70 y: The OPTILIP Study. Am J Clin Nutr, 2006; 84:1290–1298.
20.
SadovskyR, Kris-EthertonP. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides. Postgrad Med, 2009; 121:145–153.
21.
BarterP, GinsbergHN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol, 2008; 102:1040–1045.
22.
JahromiMAF, RayAB. Antihyperlipidemic effect of flavonoids from Pterocarpus marsupium. J Nat Prod, 1993; 56:989–999.
23.
ZhaoSP, LiuL, ChengYCet al.Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation, 2004; 110:915–920.
24.
LuL, ZhouJZ, WangL, ZhangTX. Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension. Chin J Integr Med, 2009; 15:266–271.
25.
FanXF, DengYQ, YeLet al.Effect of Xuezhikang capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chin J Integr Med, 2010; 16:119–123.
26.
LiuJD, LiuZQ, CuiLQet al.Short-term application of Xuezhikang on plasma levels of C-reactive protein in perioperative percutaneous coronary intervention. Chin J Cardiol (Chin), 2006; 34:406.
27.
YaoQH, CuiCC, WangJK. Effect of xuezhikang on blood lipids, serum oxidized low density lipoprotein, C-reactive protein and fibrinogen in patients with unstable angina pectoris. Chin J Integr Tradit West Med (Chin), 2003; 23:750–752.
28.
HuangJ, WangMH, PengXPet al.Effects of Xuezhikang on serum levels of high sensitive-C reactive protein, matrix metalloproteinase-9 and lipoprotein in patients with acute coronary syndrome. Chin J Integr Tradit West Med (Chin), 2006; 26:221–223.
29.
JianJ, HaoX, DengCet al.The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia. Chin J Intern Med (Chin), 1999; 38:517–519.
30.
LaufsU, La FataV, PlutzkyJ, LiaoJK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 1998; 97:1129–1135.
31.
ArntzeniusAC, KromhoutD, BarthJDet al.Diet, lipoproteins, and the progression of coronary atherosclerosis: The Leiden Intervention Trial. NEJM, 1985; 312:805–811.
32.
CarpentierYA, PortoisL, MalaisseWJ. n-3 fatty acids and the metabolic syndrome. Am J Clin Nutr, 2006; 83,6 suppl:1499S–1504S.
33.
HeK, LiuK, DaviglusMLet al.Associations of dietary long-chain n-3 polyunsaturated fatty acids and fish with biomarkers of inflammation and endothelial activation (from the Multi-Ethnic Study of Atherosclerosis [MESA])Am J Cardiol, 2009; 103:1238–1243.
34.
VedinI, CederholmT, Freund LeviYet al.Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: The OmegAD study. Am J Clin Nutr, 2008; 87:1616–1622.
35.
HeK, LiuK, DaviglusMLet al.Intakes of long-chain n-3 polyunsaturated fatty acids and fish in relation to measurements of subclinical atherosclerosis. Am J Clin Nutr, 2008; 88:1111–1118.
36.
HilpertKF, WestSG, Kris-EthertonPMet al.Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes. Am J Clin Nutr, 2007; 85:369–376.
37.
ZhaoG, EthertonTD, MartinKRet al.Dietary alpha-linolenic acid inhibits proinflammatory cytokine production by peripheral blood mononuclear cells in hypercholesterolemic subjects. Am J Clin Nutr, 2007; 85:385–391.
38.
DjousséL, FolsomAR, ProvinceMAet al.Dietary linolenic acid and carotid atherosclerosis: The National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr, 2003; 77:819–825.
39.
BouwensM, van de RestO, DellschaftNet al.Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr, 2009; 90:415–424.
40.
XiaoLZ, XuX, LaiSYet al.Protective effects of soy isoflavones on atherosclerosis in ovariectomized rabbits and possibly involved mechanism. South China J Cardiovasc Dis (Chin), 2004; 10:144–145.
41.
LokeWM, HodgsonJM, ProudfootJMet al.Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr, 2008; 88:1018–1025.
42.
FuchsD, VafeiadouK, HallWL, DanielH, WilliamsCM, SchrootJHet al.Proteomic biomarkers of peripheral blood mononuclear cells obtained from postmenopausal women undergoing an intervention with soy isoflavones. Am J Clin Nutr, 2007; 86:1369–1375.
43.
NascaMM, ZhouJR, WeltyFK. Effect of soy nuts on adhesion molecules and markers of inflammation in hypertensive and normotensive postmenopausal women. Am J Cardiol, 2008; 102:84–86.
44.
LiJJ, ZhangZY. The progress of anti-atherosclerosis of magnesium. Stud Trace Elem Health (Chin), 2003; 20:49–51.
45.
SchnabelR, LubosE, MessowCMet al.Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease: The SElenium Therapy in Coronary Artery disease Patients (SETCAP) Study. Am Heart J, 2008; 156:1201.e1–11.
46.
YunBS, ChoY, LeeIKet al.Sterins A and B, new antioxidative compounds from Stereum hirsutum. J Antibiot (Tokyo), 2002; 55:208–210.
47.
YaoZL, ZhuCC, WanXQ. Clinical research of Xuezhikang joint sport in treatment of steatohepatitis who had symptoms. Chin J Modern Med (Chin), 2006; 16:253–256.
48.
HongXZ, LiLD, WuLM. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol, 2007; 34:27–35.
49.
China Consensus Group on the Clinical Application of Xuezhikang Capsule. China consensus on the clinical application of Xuezhikang capsule. Chin J Intern Med (Chin), 2009; 48:171–174.
50.
TipoeGL, LeungTM, LiongECet al.Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice. Toxicology, 2010; 273:45–52.
51.
KimMH, KangKS, LeeYS. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br J Nutr, 2010; 104:1333–1342.
HongMY, SeeramNP, ZhangY, HeberD. Anticancer effects of Chinese red yeast rice versus monacolin K alone on colon cancer cells. J Nutr Biochem, 2008; 19:448–458.
54.
HardmanWE. (N-3) fatty acids and cancer therapy. J Nutr, 2004; 134:3427S.
55.
JiangWG, BryceRP, HorrobinDF, ManselRE. Regulation of tight junction permeability and occludin expression by polyunsaturated fatty acids. Biochem Biophys Res Commun, 1998; 244:414–420.
56.
MehtaSP, BoddyAP, CookJet al.Effect of n-3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus. Am J Clin Nutr, 2008; 87:949–956.
57.
ZhuRX, ZhangSL, JinYS. Recent advances in the study on antitumor effects of flavonoids. Drugs Clinic, 2010; 25:5–10.
58.
ZengS, YangY, GuoQL. Mechanism of flavonoids-induced apoptosis in cancer cells and related experimental researches: A review. Prog Pharm Sci (Chin), 2009; 33:402–407.
59.
ShenDL, LiB, LiJGet al.Anticancer mechanism of selenium: Recent progress. Chin J Cancer Biother (Chin), 2008; 15:598–600.
60.
SubbiahMT. Dietary plant sterols: Current status in human and animal sterol metabolism. Am J Clin Nutr, 1973; 26:219–225.
61.
KaholsK, KangasL, HiltunenR. Ergosterol peroxide, an active compound from Inonutus radiatus. Planta Med, 1989; 55:389–390.
62.
DaiXH, XueXY, WangLet al.The effects of Xuezhikang on insulin sensitivity for patients with hypertension complicated with dyslipidemia. Chin J Cardiol (Chin), 2000; 20:692–693.
63.
CarpentierYA, PortoisL, MalaisseWJ. N-3 fatty acids and the metabolic syndrome. Am J Clin Nutr, 2006; 83,6 suppl:1499S–1504S.
64.
StirbanA, NandreanS, GöttingCet al.Effects of n-3 fatty acids on macro- and microvascular function in subjects with type 2 diabetes mellitus. Am J Clin Nutr, 2010; 91:808–813.
65.
LiuZM, ChenYM, HoSCet al.Effects of soy protein and isoflavones on glycemic control and insulin sensitivity: A 6-mo double-blind, randomized, placebo-controlled trial in postmenopausal Chinese women with prediabetes or untreated early diabetes. Am J Clin Nutr, 2010; 91:1394–401.
66.
BarbagalloM, DominguezLJ, ResnickLM. Magnesium metabolism in hypertension and type 2 diabetes mellitus. Am J Ther, 2007; 14:375–385.
67.
KimDJ, XunP, LiuKet al.Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care, 2010; 33:2604–2610.
68.
ZhangM. Hypoglycemic effect of selenium-enriched compound SOD green tea in diabetic rats. Parenter Enteral Nutr (Chin), 2009; 16:109.
69.
WangJM, LvXY. Effects of Xuezhikang on left ventricular and remodeling for patients with hypertension. Clin Focus (Chin), 2000; 15:645–646.
70.
GongC, HuangSL, HuangJFet al.Effects of combined therapy of Xuezhikang Capsule and Valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence. Chin J Integr Med, 2010; 16:114–118.
71.
YeP, WuCE, ShengL, LiH. Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension. J Altern Complement Med, 2009; 15:719–725.
72.
RamasubbuK, MannDL. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol, 2006; 47:342–344.
73.
ZhouFY, ZhangJ, SongTet al.Effects of xuezhikang and simvastatin on cerebral ischemia-reperfusion injury in rat. China J Chin Mater Med (Chin), 2006; 31:1447–1450.
74.
TianF, QiXX, ZhengZH. α-linolenic acid on learning and memory function and hippocampal neurons of rats. Chin J Geriatrics (Chin), 2009; 29:664–666.
75.
FéartC, PeuchantE, LetenneurLet al.Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: Data from the Bordeaux sample of the Three-City Study. Am J Clin Nutr, 2008; 87:1156–1162.
TymianskiM, TatorCH. Normal and abnormal calcium homeostasis in neuron: A basis for the pathophysiology of traumatic and ischemic CNS injury. Neurosurgery, 1996; 38:1176–1195.
78.
CaoZX, LiaoPY. Treatment of Xuezhikang on nephrotic syndrome for children in hyperlipidemia with 30 cases. Chin J Cardiol (Chin), 2007; 27:855–856.
79.
LiuZX, LinZ, WuYXet al.Effects of Xuezhikang on microalbuminuria in patients with youth obesity. World J Integr Tradit West Med (Chin), 2007; 12:719–721.
80.
PatelS, MasonRM, SuzukiJet al.Inhibitory effect of statins on renal epithelial-to-mesenchymal transition. Am J Nephrol, 2006; 26:381–387.
81.
QianJL, ZhangMF. Progress of n-3 polyunsaturated fatty acids on chronic kidney disease. Chin J Integr Tradit West Nephrol (Chin), 2009; 1095–1097.
82.
WangJ, LiangY, ZhangYCet al.Experimental study of α-linolenic acid inhibitory effect on calcium oxalate crystalization in rats. Chin J Urol (Chin), 2004; 25:163–165.
83.
LuL, ZhouJZ, WangL, ZhangTX. Effects of Xuezhikang and pravastatin on circulating endothelial progenitor cells in patients with essential hypertension. Chin J Integr Med, 2009; 15:266–271.
84.
WongRW, RabieB. Chinese red yeast rice (Monascus purpureus-fermented rice) promotes bone formation. Chin Med, 2008; 3:4.
85.
MariniH, BittoA, AltavillaDet al.Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: A follow-up study. J Clin Endocrinol Metab, 2008; 93:4787–4796.
86.
MundyGR. Nutritional modulators of bone remodeling during aging. Am J Clin Nutr, 2006; 83:427S–430S.
87.
LauretaniF, SembaRD, BandinelliSet al.Association of low plasma selenium concentrations with poor muscle strength in older community-dwelling adults: The InCHIANTI Study. Am J Clin Nutr, 2007; 86:347–352.
88.
VirtanenJK, MursuJ, VoutilainenS, TuomainenTP. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation, 2009; 120:2315–2321.
89.
WaldNJ, WaldDS. The polypill concept. Heart, 2010; 96:1–4.
